Skip to main content
SpringerLink
Log in

Nonmyeloablative stem cell transplantation in follicular B-cell lymphoma

  • Published:
Current Hematologic Malignancy Reports Aims and scope Submit manuscript

Abstract

Myeloablative allogeneic stem cell transplantation carries the promise of long-term disease control by graft-versus-lymphoma (GVL) immunity but is associated with a 30% to 40% risk of transplant-related mortality. Nonmyeloablative stem cell transplantation (NST) aims to exploit the GVL effect without the attendant toxicity of myeloablative conditioning. At the M.D. Anderson Cancer Center, the standard NST conditioning regimen for patients with follicular lymphoma is fludarabine, cyclophosphamide, and rituximab (FCR). Using this regimen, transplant-related mortality is currently 10%, and 85% of patients remain alive without disease at 3 to 4 years. This review discusses the current issues in NST for follicular lymphomas, including the optimization of conditioning intensity, the use of rituximab in immunomodulation, and the role of donor lymphocyte infusion.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Horning SJ: Natural history of and therapy for the indolent non-Hodgkin’s lymphomas. Semin Oncol 1993, 20:75–88.

    PubMed  CAS  Google Scholar 

  2. Zinzani PL, Pulsoni A, Perrotti A, et al.: Fludarabine plus mitoxantrone with and without rituximab versus CHOP with and without rituximab as front-line treatment for patients with follicular lymphoma. J Clin Oncol 2004, 22:2654–2661.

    Article  PubMed  CAS  Google Scholar 

  3. McLaughlin P, Grillo-Lopez AJ, Link BK, et al.: Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program. J Clin Oncol 1998, 16:2825–2833.

    PubMed  CAS  Google Scholar 

  4. Kaminski MS, Tuck M, Estes J, et al.: 131I-tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med 2005, 352:441–449.

    Article  PubMed  CAS  Google Scholar 

  5. Van Besien K, Loberiza FRJ, Bajorunaite R, et al.: Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma. Blood 2003, 102:3521–3529.

    Article  PubMed  CAS  Google Scholar 

  6. Peniket AJ, Ruiz de Elvira MC, Taghipour G, et al.: An EBMT registry matched study of allogeneic stem cell transplants for lymphoma: allogeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality rate than autologous transplantation. Bone Marrow Transplant 2003, 31:667–678.

    Article  PubMed  CAS  Google Scholar 

  7. Hosing C, Saliba RM, McLaughlin P, et al.: Long-term results favor allogeneic over autologous hematopoietic stem cell transplantation in patients with refractory or recurrent indolent non-Hodgkin’s lymphoma. Ann Oncol 2003, 14:737–744.

    Article  PubMed  CAS  Google Scholar 

  8. Toze CL, Barnett MJ, Connors JM, et al.: Long-term disease-free survival of patients with advanced follicular lymphoma after allogeneic bone marrow transplantation. Br J Haematol 2004, 127:311–321.

    Article  PubMed  Google Scholar 

  9. Bierman PJ, Sweetenham JW, Loberiza FRJ, et al.: Syngeneic hematopoietic stem-cell transplantation for non-Hodgkin’s lymphoma: a comparison with allogeneic and autologous transplantation—The Lymphoma Working Committee of the International Bone Marrow Transplant Registry and the European Group for Blood and Marrow Transplantation. J Clin Oncol 2003, 21:3744–3753.

    Article  PubMed  Google Scholar 

  10. Van Besien KW, de Lima M, Giralt SA, et al.: Management of lymphoma recurrence after allogeneic transplantation: the relevance of graft-versus-lymphoma effect. Bone Marrow Transplant 1997, 19:977–982.

    Article  PubMed  Google Scholar 

  11. Mandigers CM, Verdonck LF, Meijerink JP, et al.: Graft-versus-lymphoma effect of donor lymphocyte infusion in indolent lymphomas relapsed after allogeneic stem cell transplantation. Bone Marrow Transplant 2003, 32:1159–1163.

    Article  PubMed  CAS  Google Scholar 

  12. Khouri IF, Keating M, Korbling M, et al.: Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. J Clin Oncol 1998, 16:2817–2824.

    PubMed  CAS  Google Scholar 

  13. Khouri IF, Saliba RM, Giralt SA, et al.: Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality. Blood 2001, 98:3595–3599.

    Article  PubMed  CAS  Google Scholar 

  14. Khouri IF, Lee MS, Saliba RM, et al.: Nonablative allogeneic stem cell transplantation for chronic lymphocytic leukemia: impact of rituximab on immunomodulation and survival. Exp Hematol 2004, 32:28–35.

    Article  PubMed  CAS  Google Scholar 

  15. Khouri IF, Saliba RM, Hosing CM, et al.: Autologous stem cell (AUTO) vs non-myeloablative allogeneic transplantation (NMT) after high-dose rituximab (HD-R)-containing conditioning regimens for relapsed chemosensitive follicular lymphoma (FL) [abstract]. Blood (ASH Annual Meeting Abstracts) 2005, 106:Abstract 48.

  16. Khouri IF, Lee MS, Saliba RM, et al.: Non-myeloablative allogeneic transplantation (NMT) with T-cell replete graft for relapsed chemosensitive follicular lymphoma (FL): Donor lymphocyte infusion (DLI) to convert stable mixed chimerism to full donor chimerism is not necessary in the absence of disease progression [abstract]. Blood (ASH Annual Meeting Abstracts) 2005, 106:Abstract 3659.

  17. Demidem A, Lam T, Alas S, et al.: Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B-cell lymphoma cell line to cell killing by cytotoxic drugs. Cancer Biother Radiopharm 1997, 12:177–186.

    Article  PubMed  CAS  Google Scholar 

  18. Alas S, Bonavida B: Rituximab inactivates signal transducer and activation of transcription 3 (STAT3) activity in B-non-Hodgkin’s lymphoma through inhibition of the interleukin 10 autocrine/paracrine loop and results in down-regulation of Bcl-2 and sensitization to cytotoxic drugs. Cancer Res 2001, 61:5137–5144.

    PubMed  CAS  Google Scholar 

  19. Di Gaetano N, Xiao Y, Erba E, et al.: Synergism between fludarabine and rituximab revealed in a follicular lymphoma cell line resistant to the cytotoxic activity of either drug alone. Br J Haematol 2001, 114:800–809.

    Article  PubMed  Google Scholar 

  20. Maloney DG, Grillo-Lopez AJ, White CA, et al.: IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin’s lymphoma. Blood 1997, 90:2188–2195.

    PubMed  CAS  Google Scholar 

  21. Hsu FJ, Komarovskaya M: CTLA4 blockade maximizes antitumor T-cell activation by dendritic cells presenting idiotype protein or opsonized anti-CD20 antibody-coated lymphoma cells. J Immunother (1997) 2002, 25:455–468.

    Article  CAS  Google Scholar 

  22. Schultz KR, Paquet J, Bader S, HayGlass KT: Requirement for B cells in T cell priming to minor histocompatibility antigens and development of graft-versus-host disease. Bone Marrow Transplant 1995, 16:289–295.

    PubMed  CAS  Google Scholar 

  23. O’Brien SM, Kantarjian H, Thomas DA, et al.: Rituximab dose-escalation trial in chronic lymphocytic leukemia. J Clin Oncol 2001, 19:2165–2170.

    PubMed  CAS  Google Scholar 

  24. Byrd JC, Murphy T, Howard RS, et al.: Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. J Clin Oncol 2001, 19:2153–2164.

    PubMed  CAS  Google Scholar 

  25. Kusumi E, Kami M, Kanda Y, et al.: Reduced-intensity hematopoietic stem-cell transplantation for malignant lymphoma: a retrospective survey of 112 adult patients in Japan. Bone Marrow Transplant 2005, 36:205–213.

    PubMed  CAS  Google Scholar 

  26. Vigouroux S, Michallet M, Porcher R, et al.: Long-term outcomes after reduced-intensity conditioning allogeneic stem cell transplantation for low-grade lymphoma: a survey by the French Society of Bone Marrow Graft Transplantation and Cellular Therapy (SFGM-TC). Haematologica 2007, 92:627–634.

    Article  PubMed  Google Scholar 

  27. Faulkner RD, Craddock C, Byrne JL, et al.: BEAM-alemtuzumab reduced-intensity allogeneic stem cell transplantation for lymphoproliferative diseases: GVHD, toxicity, and survival in 65 patients. Blood 2004, 103:428–434.

    Article  PubMed  CAS  Google Scholar 

  28. Rodriguez R, Nademanee A, Ruel N, et al.: Comparison of reduced-intensity and conventional myeloablative regimens for allogeneic transplantation in non-Hodgkin’s lymphoma. Biol Blood Marrow Transplant 2006, 12:1326–1334.

    Article  PubMed  Google Scholar 

  29. Van Besien K, Carreras J, Zhang MJ, et al.: Reduced intensity vs myeloablative conditioning for HLA matched sibling transplantation in follicular lymphoma [abstract]. Blood (ASH Annual Meeting Abstracts) 2005, 106:Abstract 656.

  30. Robinson SP, Goldstone AH, Mackinnon S, et al.: Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation. Blood 2002, 100:4310–4316.

    Article  PubMed  CAS  Google Scholar 

  31. Morris E, Thomson K, Craddock C, et al.: Outcomes after alemtuzumab-containing reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphoma. Blood 2004, 104:3865–3871.

    Article  PubMed  CAS  Google Scholar 

  32. Lundin J, Porwit-MacDonald A, Rossmann ED, et al.: Cellular immune reconstitution after subcutaneous alemtuzumab (anti-CD52 monoclonal antibody, CAMPATH-1H) treatment as first-line therapy for B-cell chronic lymphocytic leukaemia. Leukemia 2004, 18:484–490.

    Article  PubMed  CAS  Google Scholar 

  33. Maris MB, Sandmaier BM, Storer B, et al.: Allogeneic hematopoietic cell transplantation (HCT) after nonmyeloablative conditioning for relapsed or refractory follicular lymphoma [abstract]. Blood (ASH Annual Meeting Abstracts) 2005, 106:Abstract 1130.

  34. Branson K, Chopra R, Kottaridis PD, et al.: Role of nonmyeloablative allogeneic stem-cell transplantation after failure of autologous transplantation in patients with lymphoproliferative malignancies. J Clin Oncol 2002, 20:4022–4031.

    Article  PubMed  Google Scholar 

  35. Escalon MP, Champlin RE, Saliba RM, et al.: Nonmyeloablative allogeneic hematopoietic transplantation: a promising salvage therapy for patients with non-Hodgkin’s lymphoma whose disease has failed a prior autologous transplantation. J Clin Oncol 2004, 22:2419–2423.

    Article  PubMed  Google Scholar 

  36. Khouri IF, Saliba RM, Hosing C, et al.: Efficacy and safety of yttrium 90 (90 Y) ibritumomab tiuxetan in autologous and nonmyeloablative stem cell transplantation (NST) for relapsed non-Hodgkin’s lymphoma (NHL) [abstract]. Blood (ASH Annual Meeting Abstract) 2006, 108:Abstract 315.

  37. Baron F, Maris MB, Sandmaier BM, et al.: Graft-versus-tumor effects after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning. J Clin Oncol 2005, 23:1993–2003.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Stem Cell Transplantation and Cellular Therapy, Unit 423, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX, 77030, USA

    Issa Khouri

Authors
  1. Constantine S. Tam
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Issa Khouri
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Issa Khouri.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Tam, C.S., Khouri, I. Nonmyeloablative stem cell transplantation in follicular B-cell lymphoma. Curr Hematol Malig Rep 2, 225–231 (2007). https://doi.org/10.1007/s11899-007-0031-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11899-007-0031-1

Keywords

Search

Navigation